J. Safra Sarasin Holding’s BioMarin Pharmaceuticals BMRN Stock Holding History

J. Safra Sarasin Holding’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.54M	Sell	26,891 -16,828	-38%	-$922K	0.02%	311
2026 Q1	$2.47M	Buy	43,719 +12,859	+42%	+$750K	0.04%	170
2025 Q4	$1.83M	Sell	30,860 -4,094	-12%	-$223K	0.03%	211
2025 Q3	$1.89M	Sell	34,954 -15,554	-31%	-$890K	0.03%	220
2025 Q2	$2.78M	Buy	50,508 +18,203	+56%	+$1.07M	0.05%	174
2025 Q1	$2.28M	Sell	32,305 -23,167	-42%	-$1.56M	0.04%	207
2024 Q4	$3.65M	Sell	55,472 -13,743	-20%	-$921K	0.06%	158
2024 Q3	$4.87M	Buy	69,215 +42,525	+159%	+$3.55M	0.08%	137
2024 Q2	$2.2M	Buy	+26,690	New	+$2.22M	0.04%	215

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

J. Safra Sarasin Holding's BMRN Position: Q2 2026 in Review

J. Safra Sarasin Holding reduced its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q2 2026, selling an estimated $922K and leaving 26,891 shares worth $1.54M. The position accounts for 0.02% of the portfolio, ranked #311.

J. Safra Sarasin Holding first reported a position in BMRN in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.87M in Q3 2024. 566 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

J. Safra Sarasin Holding held 26,891 shares of BioMarin Pharmaceuticals worth $1.54M as of Q2 2026.
J. Safra Sarasin Holding sold 16,828 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $922K.
BioMarin Pharmaceuticals made up 0.02% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #311 holding.
J. Safra Sarasin Holding first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
J. Safra Sarasin Holding's BioMarin Pharmaceuticals position peaked at $4.87M in Q3 2024.
566 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.